Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia.
We previously demonstrated that severe hypoxia inhibits growth of Chronic Myeloid Leukemia (CML) cells and selects stem cells where BCR/Abl(protein) is suppressed, although mRNA is not, so that hypoxia-selected stem cells, while remaining leukemic, are independent of BCR/Abl signaling and thereby re...
Guardado en:
Autores principales: | Michele Tanturli, Serena Giuntoli, Valentina Barbetti, Elisabetta Rovida, Persio Dello Sbarba |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/26aef4698a424215bb706a55d7c289d4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia
por: Kyoko Ito, et al.
Publicado: (2021) -
METABOLIC STATE OF BLOOD LYMPHOCYTES IN CHRONIC MYELOID LEUKEMIA AND CHRONIC LYMPHOID LEUKEMIA
por: O. V. Smirnova, et al.
Publicado: (2014) -
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
por: Anagnostou T, et al.
Publicado: (2017) -
Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Radhakrishnan Ramchandren, et al.
Publicado: (2009) -
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]
por: Anagnostou T, et al.
Publicado: (2018)